We analyzed transcriptional changes in 4 prostate cancer cell lines following treatment with the BET inhibitor I-BET762 using Affymetrix Human Genome U133 Plus 2.0 Arrays.
Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.
Cell line, Time
View SamplesTranscriptional changes were analyzed in two colorectal cancer, two pancreatic cancer, and one small cell lung cancer cell line following treatment with the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib using Affymetrix Human Genome U133 Plus 2.0 Arrays.
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Cell line, Treatment, Time
View Samples